 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...172173174175176177178179180181182...203204» |
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. (Pubmed Central) - Jun 7, 2019
...This post hoc analysis of data fromEXTEND (extend the safety and efficacy of adalimumab through endoscopic healing), a placebo (PBO)-controlled, randomized trial of adalimumab (ADA) for mucosal healing, included adults with moderate-to-severe CD...Site-based evaluation was associated with lower remission rates versus central reading in the PBO group and, thus, greater ADA-related treatment effects. This analysis is the first to demonstrate that increasing the stringency of clinical and endoscopic endpoint definitions in CD trials, especially lowering SF or SES-CD definitions, reduces the ability to detect treatment-related change in CD activity; focus on endpoints that reflect clinical change is warranted.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, Real-World Evidence: Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. (Pubmed Central) - Jun 7, 2019
In this cohort, 56% of patients with UC required ADM dose escalation with a 60% success rate. Of note, most patients could be successfully de-escalated later on.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Adult Autoinmune Enteropathy and Colitis: A Challenge Successfully Treated With Adalimumab. (Pubmed Central) - Jun 7, 2019
Of note, most patients could be successfully de-escalated later on. No abstract available
- | Retrospective data, Review, Journal: Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. (Pubmed Central) - Jun 7, 2019
Results suggest that brodalumab is associated with a higher likelihood of sustained PASI response, including complete clearance, at week 52 than comparators. Further long-term active-comparator RCT data are required to better assess relative efficacy across therapies.
- | Olumiant (baricitinib) / Incyte, Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. (Pubmed Central) - Jun 7, 2019
In csDMARD-IR patients, significant benefit was seen with baricitinib 4 mg (≤SDC: 87.2% vs 73.2% placebo; p≤0.01). Treatment with once-daily baricitinib resulted in low rates of radiographic progression for up to 2 years.
- | Humira (adalimumab) / Eisai, AbbVie
Journal, HEOR: Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry. (Pubmed Central) - Jun 7, 2019
...However, not much is known about long-term cost-effectiveness of different T2T strategies.We model the 5-year costs and effects of a step-up approach (MTX mono - > MTX + csDMARD combination - > Adalimumab - > second anti-TNF) and an initial combination therapy approach (MTX + csDMARD - > MTX + csDMARD higher dose - > anti-TNFs) from the healthcare and societal perspectives, by adapting a previously validated Markov model...Initial combination therapy was found favourable over step-up therapy in the treatment of Rheumatoid Arthritis, when considering cost-effectiveness. Initial combination therapy resulted in more utility at a lower cost over 5 years.
- || Humira (adalimumab) / Eisai, AbbVie
Humira Introduces New Citrate-Free Formulation in the Q1 2019 Biologics and Non-Biologics for GI Indications @abbvie #dtw #marketHighlights #abbvie #Humira #citratefree #adalimumab #GI #GIIndications #Q12019 #BiologicsandNonBiologics #BiologicsandNonBiologicsforGIIndications (Twitter) - Jun 7, 2019
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. (Pubmed Central) - Jun 7, 2019
We report a high incidence of anti-TNF-associated psoriasis that was associated with female gender, foregut disease location, and fistulizing and stricturing disease behavior. More prospective studies and genetic analyses evaluating possible pathophysiologic underpinnings of this problem are needed.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. (Pubmed Central) - Jun 7, 2019
More prospective studies and genetic analyses evaluating possible pathophysiologic underpinnings of this problem are needed. This study demonstrates that higher maintenance adalimumab concentrations are associated with objective therapeutic outcomes in IBD.
- | Clinical, Journal: The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report. (Pubmed Central) - Jun 6, 2019
This study demonstrates that higher maintenance adalimumab concentrations are associated with objective therapeutic outcomes in IBD. An efficient way to effectively treat patients with complex autoimmune arthropathies, and avoid irreversible disability, is to know their leukocytes' secretome to identify abnormally secreted cytokines and personalize their biotherapy, as exemplified by this case report.
- ||||| Humira (adalimumab) / Eisai, AbbVie
Clinical: New & surprising RCT result! #Phototherapy and #Humira improve skin QOL and overall QOL compared to placebo in #psoriasis pts, however, phototherapy treated pts achieved MORE improvement in overall HrQOL compared to patients treated with #Humira. #dermtwitter @AADmember (Twitter) - Jun 6, 2019
- |||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Head-to-Head, Video: VIDEO: Dr Bruce Sands discusses his #DDW19 presentation on VARSITY trial, which shows superiority of vedolizumab over adalimumab in ulcerative colitis https://t.co/9xPNFCageW (Twitter) - Jun 6, 2019
- | Clinical, Journal, HEOR: Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. (Pubmed Central) - Jun 5, 2019
An efficient way to effectively treat patients with complex autoimmune arthropathies, and avoid irreversible disability, is to know their leukocytes' secretome to identify abnormally secreted cytokines and personalize their biotherapy, as exemplified by this case report. Abatacept-treated RA patients appeared to have the poorest health status yet often had the lowest increase from baseline in healthcare costs and longest duration of biologic persistence.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Clinical, PK/PD data, Journal: Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. (Pubmed Central) - Jun 5, 2019
Vedolizumab/anti-TNF co-exposure did not generate new safety signals during 14-weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. These observations may aid the design of future co-biologics trials and also suggest that a deliberate waiting-interval between anti-TNF cessation and subsequent vedolizumab initiation may not be warranted.
- | Avastin (bevacizumab) / Roche, Humira (adalimumab) / Eisai, AbbVie
Journal: A novel online four-dimensional SECxSEC-IMxMS methodology for characterization of monoclonal antibody size variants. (Pubmed Central) - Jun 5, 2019
In this specific context, monomeric conformers were detected by IM-MS as HMWS or LMWS. Altogether, our results empha-size the power of comprehensive 2D LCxLC setups hyphenated to IMxMS in non-denaturing conditions with unprece-dented performance including: i) maintaining optimal SEC performance (under classical non volatile salt conditions), ii) performing online native MS identification, and iii) providing IM-MS conformational characterization of all sepa-rated size variants.
- || Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
It's a bit of a non-story though, pharma have to choose whether or not to proceed with development for a given indication constantly. I suspect if none of pfizer (enbrel), janssen (remicide), Abbot (humira) or others are pursuing this it's safe to say that it's a long shot. (Twitter) - Jun 5, 2019
- ||| Pricing: Feels like pricing collusion. Drugs prescribed interchangeably, e.g. Humira & Enbrel or Humalog, Humulin, and Novolog, highly synchronized in cost changes while demonstrating some of the largest cost increases in the industry over past 6 years. @EricTopol https://t.co/RhoUp65E4q (Twitter) - Jun 5, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. (Pubmed Central) - Jun 4, 2019
Adalimumab appears to reduce the corticosteroid burden in active and inactive non-infectious uveitis in the real-world setting. Inflammatory activity at the time of adalimumab commencement may determine long-term treatment success.
- |||| Humira (adalimumab) / Eisai, AbbVie
Pricing: "More money is spent on the TNF-α inhibitor #adalimumab than any other medication in the UK and USA, with costs at list price of £462 million and $14.1 billion, respectively, in 2016." A #Rheumatology editorial by Mark D Russell, @drjamesgalloway, & @drdj https://t.co/OS4LU7cub9 (Twitter) - Jun 4, 2019
- || Humira (adalimumab) / Eisai, AbbVie
Reimbursement: why are humira pens $2,000 each without insurance (Twitter) - Jun 3, 2019
- ||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Jun 3, 2019
P4, N=10, Active, not recruiting, Sponsor: Dr. Larry W. Moreland
Inflammatory activity at the time of adalimumab commencement may determine long-term treatment success. Recruiting --> Active, not recruiting | N=90 --> 10
- |||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Adverse events: Not something I have noticed. No side effects other than lack of white cells with adalimumab and ustekinumab. Same with infliximab plus urticaria and pruritus 😬 (Twitter) - Jun 2, 2019
- || Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Hungry all the time, Sugar craving on Humira and now Ustekinumab.... (Twitter) - Jun 2, 2019
- | Humira (adalimumab) / Eisai, AbbVie
@savvy_coop has a gig for RA & Humira! (Twitter) - Jun 1, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Fab thanks so much Kay, really useful to know!!! Thought Humira lasted a while but didnt realise it was as long as 14 days! (Twitter) - Jun 1, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. (Pubmed Central) - May 31, 2019
Adalimumab is effective for achieving initial and durable resolution of any EIM and, in particular, arthritis/arthralgia in patients with moderate to severe CD. Predictors of EIM resolution included adalimumab treatment and moderate disease severity.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Biomarker, Review, Journal: Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis. (Pubmed Central) - May 31, 2019
Our gene ontology analysis shows that these networks have roles in apoptotic signalling, response to oxidative stress and inflammation pathways. We conclude that a more systematic approach with genome-wide search of genomic and expression biomarkers in the same patients is needed in future studies.
- | Journal: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists. (Pubmed Central) - May 31, 2019
There was consensus with use of 4 biologics - adalimumab (81%), certolizumab (80%), etanercept (83%), and infliximab (76%) - in planned pregnancies but uncertainty on when they should be discontinued and their use in unplanned pregnancies. This national survey shows consensus among rheumatologists on the use of some csDMARDs and biologics/small molecules in IA patients planning pregnancy but varied knowledge on when to discontinue and what to do in unplanned pregnancies.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. (Pubmed Central) - May 31, 2019
These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
- | Journal: Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. (Pubmed Central) - May 30, 2019
These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge. Ex-vivo inhibition of cytokine production by bDMARDs is unable to help prediction of treatment response to bDMARDs in RA.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Bringing Humira (Its Price) Down a Peg. (Pubmed Central) - May 30, 2019
Very hard. Humira faces competition in Europe, but it will probably take years before its market share is challenged in the United States.
- || Humira (adalimumab) / Eisai, AbbVie
@abbvie Look what I can do! Thank you, humira! (Twitter) - May 30, 2019
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa (clinicaltrials.gov) - May 29, 2019
P=N/A, N=80, Recruiting, Sponsor: AbbVie
Humira faces competition in Europe, but it will probably take years before its market share is challenged in the United States. Not yet recruiting --> Recruiting
- | Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (Pubmed Central) - May 29, 2019
No significant differences in drug discontinuation were observed between categories. Clinical trial effectiveness and safety outcomes are not representative of real-world patients in BADBIR patients categorized as ineligible for such trials.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA. (Pubmed Central) - May 29, 2019
Taken together, we developed innovative cELISAs enabling quantification of functional and neutralizing anti-drug antibodies, comparable to RGA. The association between cELISA results and loss of drug response in patients identified clinically important anti-drug antibodies, as measured by cELISA.
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. (Pubmed Central) - May 29, 2019
Women with moderate to severe refractory IC/BPS were more likely to experience significant improvement in symptoms with certolizumab pegol compared with placebo therapy. Further investigation of certolizumab pegol for the treatment of IC/BPS is warranted with a larger, longer, multicenter, randomized, placebo-controlled trial.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Observational data, Retrospective data, Journal: Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. (Pubmed Central) - May 29, 2019
The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). (Pubmed Central) - May 29, 2019
Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX (adjusted OR: 0.72, 95%CI 0.21-2.44, p=0.600) at 12 weeks; after one year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX (adjusted OR: 1.23, 95%CI 0.54-2.86, p=0.620). In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.
- | Clinical, Journal: Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. (Pubmed Central) - May 29, 2019
Calculations of odds ratios for residual dactylitis were significant for clazakizumab 100 mg and secukinumab in anti-TNF-naïve population. Homogenization of dactylitis assessment and use of this criterion as primary outcome are necessary to have better data on treatment efficacy in the future.
- | Humira (adalimumab) / Eisai, AbbVie, Cosentyx (secukinumab) / Novartis
Journal, HEOR: Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis. (Pubmed Central) - May 29, 2019
Secukinumab is a cost-saving treatment option compared with adalimumab in the treatment of AS in Finland. More patients could be treated with a biologic by allocating resources more efficiently.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab. (Pubmed Central) - May 29, 2019
MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Adalimumab-induced acute myeloid leukaemia in a patient with Crohn's disease. (Pubmed Central) - May 29, 2019
We present a patient with Crohn's disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.
- | Clinical, Journal: Safety of drugs used for the treatment of Crohn's disease. (Pubmed Central) - May 29, 2019
Data on vedolizumab and ustekinumab suggests these newer biologic agents are well-tolerated, however longer term data in CD is required to identify risks with extended use. Apart from methotrexate, there appears to be no adverse congenital outcomes with exposure of drugs during pregnancy.
- | Humira (adalimumab) / Eisai, AbbVie
Preclinical, Journal: Adalimumab mitigates ovarian ischemia-reperfusion injury in rats by regulating oxidative stress, apoptosis and resolution of inflammation. (Pubmed Central) - May 29, 2019
Apart from methotrexate, there appears to be no adverse congenital outcomes with exposure of drugs during pregnancy. Adalimumab therapy in rats attenuated I/R induced ovarian injury, possibly suppressing inflammation, inhibiting oxidative stress, and altering apoptotic pathways.
- | Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. (Pubmed Central) - May 29, 2019
Multimorbidity, measured by RDCI, is a negative predictor of TNFi persistence on treatment and of achieving a good clinical response. The use of RDCI may be very useful for identifying patients with RA carrying those comorbid conditions associated with poor prognostic outcomes and for defining new treatment targets in multimorbid RA patients.
- || Humira (adalimumab) / Eisai, AbbVie
Shhh 🤫! Don’t tell anyone 🤣! Just add that to the already stressful and confusing MS. Love explaining why we need the DMD to the customer ‘service’ at pharmacy. Our neighbor gets humira and I was joking about the hoops they have to go through. Been there. Are there. 😬 (Twitter) - May 26, 2019
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: National trends in prescription drug expenditures and projections for 2017. (Pubmed Central) - May 26, 2019
We project a 6.0-8.0% increase in total drug expenditures across all settings, an 11.0-13.0% increase in clinics, and a 3.0-5.0% increase in hospital drug spending in 2017. Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization's anticipated spending in 2017.
- | Clinical, Review, Journal: Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. (Pubmed Central) - May 25, 2019
The authors discuss the barriers to use of systemic agents and highlight the central importance of each patient's perspective when assessing disease severity. Additionally, practical strategies for selecting and safely initiating systemic therapy to optimize the treatment of patients with psoriasis are identified.
- || Humira (adalimumab) / Eisai, AbbVie
Has anyone else noticed or have more bleeding after using the new citrate-free Humira? @abbvie #AS #AnkylosingSpondylitis #Humira #Autoimmune (Twitter) - May 25, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab. (Pubmed Central) - May 24, 2019
P=N/A
In this observational cohort of patients with long-standing disease, MDA provided a stable and valid assessment of clinical status over 24 months. Clinicaltrials.gov, https://clinicaltrials.gov, NCT01111240.